Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript

🇺🇸 Seeking Alpha (US) —
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript

AI Summary

Connect Biopharma discussed topline results from the Seabreeze STAT study evaluating rademikibart for COPD exacerbations. The headline identifies the trial and condition but provides no details on efficacy or safety results.

Markets Health Connect Biopharma rademikibart COPD clinical trial Seabreeze STAT topline results

Read original source →